Life sciences transactions often focus on innovation and keeping that innovation alive is critical to ongoing success. In this panel, panelists will explore several different M&A and licensing models for keeping the innovation engine going including: acquired companies operating independently; option deals that maintain autonomy up to a certain development phase; milestone payments and contingent value rights; and employee retention plans. The session will engage our esteemed panelists from the pharma and biotech sectors, on their and their companies’ experiences and lessons learned, including a discussion on the M&A and licensing tactics that have been most successful.